Fair Value of Financial Instruments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 15, 2024	Aug. 31, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Option, Quantitative Disclosures [Line Items]
Unrealized loss on investment in equity securities				$ (43,564)	$ 0	$ 0
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]				General and administrative
Change in fair value of the contingent financial asset and contingent financial liabilities				$ 1,200
Changes in fair value of contingent assets and liabilities				2,699	$ 9,275	$ (34,700)
Progenics
Fair Value, Option, Quantitative Disclosures [Line Items]
Payments for prior acquisition				85,000
Progenics | Net Sales Targets for Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high			$ 70,000	70,000
Progenics | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high			5,000	5,000
Progenics | 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high			$ 10,000	$ 10,000
Progenics | Reduction due to partial settlement of 2013 Milestone Rights
Fair Value, Option, Quantitative Disclosures [Line Items]
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]				General and administrative
Change in fair value of the contingent financial asset and contingent financial liabilities				$ (1,500)
Changes in fair value of contingent assets and liabilities		$ 1
Radiopharm Theranostics Limited
Fair Value, Option, Quantitative Disclosures [Line Items]
Share price (in dollars per share)	$ 0.03		$ 0.01	$ 0.01
Unrealized loss on investment in equity securities				$ (2,600)
Equity investment, shares (in shares)	149,625,180		149,925,040	149,625,180
Equity method investments, fair value			$ 2,200	$ 2,200
Perspective Therapeutics, Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Shares owned (in shares)	11,677,339		11,677,339	11,677,339
Investment owned, fair value			$ 37,300	$ 37,300
Share price (in dollars per share)			$ 3.19	$ 3.19
Unrealized loss on investment in equity securities				$ 41,000